LISATA THERAPEUTICS, INC. — Director's Dealing 2014

May 9, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NeoStem, Inc. (NBS)
CIK: 0000320017
Period of Report: 2014-05-08

Reporting Person: Dillman Robert (See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.001 per share	10002	Direct

Footnotes

F1: Represents merger consideration issuable in connection with the May 8, 2014 closing (the "Closing") of NeoStem, Inc.'s (the "Company") acquisition of California Stem Cell, Inc. ("CSC"), pursuant to the Agreement and Plan of Merger, dated as of April 11, 2014, by and among the Company, CSC, NBS Acquisition Sub I, Inc., NeoStem Oncology, LLC, and the CSC Representative (the "Merger Agreement"). These shares are to be issued in exchange for an aggregate of 54,666 formerly outstanding shares of the common stock of CSC.